Seronegative Polyarthritis in Association With Anti-NXP2 Antibodies: A Case Series

REFERENCES

1. 1.↵
   1. Satoh M,
   2. Tanaka S,
   3. Ceribelli A,
   4. Calise SJ,
   5. Chan EK.

   A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52:1-19.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Li L,
   2. Liu C,
   3. Cheng L,
   4. Yan S,
   5. Chen H,
   6. Li Y.

   Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clin Rheumatol 2021;40:819-32.

   OpenUrl
3. 3.↵
   1. Oddis CV,
   2. Fertig N,
   3. Goel A, et al.

   Clinical and serological characterization of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum 1997;40:S139.

   OpenUrl
4. 4.↵
   1. Kimura Y,
   2. Sakai F,
   3. Nakano O, et al.

   The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem 2002;277:20611-7.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Espada G,
   2. Maldonado Cocco JA,
   3. Fertig N,
   4. Oddis CV.

   Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009;36:2547-51.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Platteel ACM,
   2. Wevers BA,
   3. Lim J, et al.

   Frequencies and clinical associations of myositis-related antibodies in the Netherlands: a one-year survey of all Dutch patients. J Transl Autoimmun 2019;2:100013.

   OpenUrlPubMed
7. 7.↵
   1. Cuchet M,
   2. Kottler D,
   3. Khoy K, et al.

   [Clinical characteristics of anti-NXP2 associated myositis in adults: a study of 6 patients]. [Article in French] Ann Dermatol Venereol 2020;147:891-7.

   OpenUrl
8. 8.↵
   1. Bodoki L,
   2. Nagy-Vincze M,
   3. Griger Z,
   4. Betteridge Z,
   5. Szöllősi L,
   6. Dankó K.

   Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014;13:1211-9.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Tansley SL,
   2. Li D,
   3. Betteridge ZE,
   4. McHugh NJ.

   The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology 2020;59:2109-14.

   OpenUrl
10. 10.↵
    1. Fiorentino DF,
    2. Chung LS,
    3. Christopher-Stine L, et al.

    Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013;65:2954-62.

    OpenUrlCrossRefPubMed